Pot Firm Tilray Speeds Expansion in Europe
(Bloomberg) -- Tilray Inc. is expanding its European leadership team and setting up a hub in Portugal, deepening its planned international reach.
The company appointed five senior members to its European team, according to a statement Friday. Arne Wilkens, a former executive at the German pharmaceuticals company AiCuris, will take on the role of vice president of business expansion in Europe.
The company said that its Cantanhede, Portugal-based campus will be the main facility for cultivation, processing, research and distribution throughout Europe and other international markets. It recently received the Good Manufacturing Practices (GMP) certification in accordance with the European Medicines Agency's standards.
Tilray currently employs more than 130 at the Portuguese facility and expects to double that by the end of this year, a spokesperson for the company said in an email.
The announcement confirms Chief Executive Brendan Kennedy's stated plans to channel investments into Europe. “The United States' and European markets are orders of magnitude larger than Canada, so while Canada will continue to be an important market for us, we expect to focus the majority of future investments on the U.S. and Europe,” Kennedy said in an interview in March.
Tilray plans to launch additional products in new markets across Europe and said it already exports to the Czech Republic, Germany, U.K., Cyprus and Croatia.
To contact the reporter on this story: Tiago Ramos Alfaro in London at talfaro1@bloomberg.net
To contact the editors responsible for this story: Sunil Kesur at skesur@bloomberg.net, Niveditha Ravi
©2019 Bloomberg L.P.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
